Abstract
There are no approved neoadjuvant treatments for localised renal cell carcinoma (RCC). Comparative data on primary tumour responses in patients treated for metastatic RCC (mRCC) may help guide selection of treatments for future prospective neoadjuvant studies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
